ADCYAP1R1 and migraine disorder: In patients with migraine, a proof-of-concept study using a PAC1 receptor monoclonal antibody did not meet its primary endpoint of migraine prevention [30], suggesting that blocking the PAC1 receptor alone was not effective for preventing migraine attacks.